[ad_1]
LeoPatrizi/E+ via Getty Images
- Lake Street Capital Markets has initiated coverage of OncoCyte with a buy saying that the diagnostics companies has a major opportunity for growth in the transplant rejection testing area.
- The firm has a $5 price target (~55% upside based on March 27 close).
[ad_2]
Source link
